Literature DB >> 31151944

Anticoagulant Medications for the Prevention and Treatment of Thromboembolism.

Lori Brien1.   

Abstract

Venous thromboembolism is a preventable medical condition associated with significant morbidity and mortality. It can lead to deep vein thrombosis, pulmonary embolism, and stroke. Thrombi develop when intravascular conditions promote activation of the coagulation system or when there is an imbalance between endogenous anticoagulants and procoagulants. Such conditions include vascular injury, inflammation, venous stasis, and hypercoagulable states. Anticoagulant medications are indicated for the prevention and treatment of venous thromboembolism. They exert their effect on clotting factors to prevent the formation of thrombi or the propagation of an existing clot. Historically, anticoagulants were limited to heparins and vitamin K antagonists. Over the past 15 years, however, several new anticoagulant medications have been introduced. This article describes commonly prescribed and newer anticoagulants available to health care professionals, including their mechanism of action, therapeutic use, unique characteristics, and available reversal agents in the event of life-threatening bleeding. ©2019 American Association of Critical-Care Nurses.

Entities:  

Keywords:  anticoagulant; anticoagulation; thromboembolism; thrombosis

Mesh:

Substances:

Year:  2019        PMID: 31151944     DOI: 10.4037/aacnacc2019867

Source DB:  PubMed          Journal:  AACN Adv Crit Care        ISSN: 1559-7768


  2 in total

1.  Effect of Clinical Nursing Pathway Intervention Based on Evidence-Based Medicine on Venous Thrombosis in Long-Term Bedridden Patients.

Authors:  Jing Chen; Yanli Wen; Lin Jin; Junwei Peng; Jin Ji
Journal:  J Healthc Eng       Date:  2022-03-14       Impact factor: 2.682

2.  Effects of the methanol fraction of modified Seonghyangjeongki-san water extract on transient ischaemic brain injury in mice.

Authors:  Eun-Jin Kang; Suin Cho; Chiyeon Lim; Byoungho Lee; Young Kyun Kim; Kyoung-Min Kim
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.